Treatment of AML in biological subgroups

Hematology

Volumn 10, Issue SUPPL. 1, 2005, Pages 281-285

  Buechner, Thomas ^a   Berdel, Wolfgang E ^a   Schoch, Claudia ^f   Haferlach, Torsten ^f   Serve, Hubert L ^a   Schnittger, Susanne ^f   Kern, Wolfgang ^f   Tchinda, Joelle ^a   Reichle, Albrecht ^b   Staib, Peter ^c   Ludwig, Wolf Dieter ^c   Aul, Carlo ^d   Sauerland, Maria Cristina ^a   Heinecke, Achim ^a   Woermann, Bernhard ^e   Hiddemann, Wolfgang ^g  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c Municipal Medical Center ^*

^d ST JOHANNES HOSPITAL   (Germany)

^e KLINIKUM BRAUNSCHWEIG   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; IMMUNOTOXIN; MITOXANTRONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; THERAPY EFFECT;

ACUTE DISEASE; AGE FACTORS; HUMANS; LEUKEMIA, MYELOID; PROGNOSIS; RISK FACTORS;

EID: 29244443473     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330512331390212     Document Type: Review

References (30)

1. Büchner T, Berdel WE, Woermann B, et al. Treatment of older patients with AML. Crit Revi Oncol/Hematol (in press)
2. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173-4179.
3. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy of acute myeloid leukaemia in first remission: results of MRC AML10 trial. The Lancet 1998;351:700-708.
4. Büchner T, Hiddemann W, Berdel WE, et al. 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): A randomized trial of the German AML Cooperative Group. J Clin Oncol 2003;21:4496-4504.
5. Büchner T, Berdel WE, Schoch C, et al. Therapeutic outcome in prognostic subgroups of de-novo acute myeloid leukemia (AML) and the role of the age factor. A study in 1834 patients of 16 to 84 years. J Clin Oncol 2005;23: Abstr. 6552
6. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-1320.
7. Schoch C, Kern W, Schnittger S, et al. The influence of age on prognosis of de-novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 2004;89:1082-1090.
8. Haferlach T, Schoch C, Löffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: Results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003;21:256-265.
9. Büchner T, Hiddemann W, Wörmann B, et al. Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group. Blood 1999;93:4116-4124.
10. Löwenberg B, van Putten W, Theobald M, et al. Effect of Priming with Granulocyte Colony-Stimulating Factor on the Outcome of Chemotherapy for Acute Myeloid Leukemia. N Eng J Med 2003;349:743-752.
11. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 trial. Blood 2003;101:64-70.
12. Hamblin T. The treatment of acute myeloid leukemia preceded by the myelodysplastic syndrome. Leuk Res 1992;16:101-108.
13. Hoyle CR, de Bastos M, Wheatley K, et al. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results form the MRC's 9th AML trial. Br J Haematol 1989;72:45-53.
14. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetic distinguishes biologic subgroups with remarkable distinct response to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-3329.
15. Leith CP, Kopecky KJ, Chen I, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDRS1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study. Blood 1999;94:1086-1099.
16. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 2000;14:796-804.
17. Schoch C, Schnittger S, Klaus J, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003;102:2395-2402.
18. Van Doorn-Khosrovani S, Erpelinck C, van Putten W, et al. High EV11 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003;101:837-845.
19. Baldus CD, Tanner SM, Ruppert AM, et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study. Blood 2003;102:1613-1618.
20. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of Flt3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93:3074-3080.
21. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-4335.
22. Mesters R, Padró T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001;98:241-243.
23. Lancet JE, Karp J. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 2003;102:3880-3889.
24. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of Gemtuzumab Ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19:3244-3254.
25. Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999;17:3569-3576.
26. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-3400.
27. Bertz H, Potthoff K, Finke J. Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia. J Clin Oncol 2003;21:1480-1484.
28. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-basend meta-analysis of patients aged 19 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004;22:3741-3750.
29. Byrd JC, Dodge K, Carroll A, et al. Patient with t(8;21)(q22:q22) and acute myeloid leukaemia have superior failure-free and ovrall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999;17: 3767-3775.
30. Byrd JC, Ruppert AS, Mrozek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukaemia and inv(16)(p13;q22): Results form CALGB 8461. J Clin Oncol 2004;22:1087-1094.